CAR-T Cell Therapy: Autologous vs Allogeneic

Every CAR-T article mentions “autologous” and “allogeneic.” Most investors nod along and never learn what the difference means for the stock. Here is what matters: autologous CAR-T is proven, approved, and generating billions in revenue, but it is capped by a manufacturing model that requires one batch per patient. Allogeneic CAR-T is cheaper, faster, and theoretically scalable to thousands of patients per manufacturing run, but the cells keep getting rejected by the patient’s immune system and losing durability after 6 to 12 months. The investor question is not which approach is better science. It is which approach generates revenue first.

The solution: autologous companies have approved drugs and revenue today but are manufacturing-capped. Allogeneic companies have no approved drugs but theoretically unlimited scale. Your job is to know which risk you are buying: execution risk for autologous, science risk for allogeneic, and price it accordingly.

Step 1: Learn what “autologous” actually means

Autologous means the CAR-T cells are the patient’s own. The process: extract the patient’s T cells via apheresis, ship them to a central manufacturing facility, engineer them with a chimeric antigen receptor (CAR), expand them, ship them back, and reinfuse them. The total vein-to-vein time runs 3 to 6 weeks. During that window, patients with aggressive blood cancers can deteriorate or die waiting.

Every dose is custom-made for one patient. The manufacturing cost of goods is estimated at roughly $95,000 per dose, though list prices are far higher: Carvykti at $465,000, Breyanzi at $410,300, Yescarta at $373,000. Scaling autologous means building more GMP suites, not running a bigger reactor.

Four autologous CAR-T therapies are FDA-approved: Yescarta (Gilead/Kite), Kymriah (Novartis), Breyanzi (Bristol Myers Squibb), and Carvykti (Johnson & Johnson/Legend Biotech). The market reached $8.95 billion in 2025. For the full company breakdown, see the CAR-T stocks analysis.

Step 2: Learn what “allogeneic” actually means

Allogeneic means the CAR-T cells come from a healthy donor, not the patient. Donor T cells are engineered, expanded, frozen, and stored. When a patient needs treatment, the cells are thawed and infused, in some cases the same day. No apheresis, no 3 to 6 week wait, no one-batch-per-patient bottleneck.

The theoretical manufacturing cost at scale is $50,000 to $100,000 per dose, versus $95,000 to $450,000 for autologous. One manufacturing run can produce hundreds of doses. This is why allogeneic is called “off-the-shelf.” It scales like a drug, not like a custom manufacturing process.

But there is a catch, and it is a big one.

Step 3: Understand the durability problem

Allogeneic CAR-T cells face two problems autologous cells do not.

Immune rejection. The patient’s immune system recognizes donor cells as foreign and attacks them. Companies engineer allogeneic CAR-T cells with gene edits to knock out the T-cell receptor and reduce rejection, but it has not been eliminated.

Limited persistence. Even when rejection is managed, allogeneic CAR-T cells do not persist as long as autologous cells. Autologous cells are the patient’s own, so they survive and function for years. Allogeneic cells are exhausted or cleared faster. Clinical data as of 2025 shows that first-generation allogeneic products achieve response rates comparable to autologous in the short term, but complete responses decline markedly after 6 to 12 months, correlating with poor CAR-T persistence. The FDA’s cellular and gene therapy products page lists the approved autologous products, with no allogeneic CAR-T among them.

This is the core problem. A CAR-T that produces a 70% complete response at month 3 but loses half those responses by month 9 is not a cure. It is a temporary remission. The durability data at 6, 12, then 18 months tells you which one you are buying.

Step 4: Map the companies on both sides

Autologous (approved, revenue, manufacturing-capped):

• Gilead (GILD): Yescarta, the first approved CAR-T. $1.4 billion in 2025 revenue for the Kite portfolio.
• Bristol Myers Squibb (BMY): Breyanzi, $1.4 billion in 2025 revenue, growing 148% year over year. But Breyanzi is 2.9% of BMY’s $48.2 billion revenue base. The stock will not move on CAR-T alone.
• Johnson & Johnson / Legend Biotech: Carvykti, $1.9 billion in 2025 revenue at $465,000 per dose.

Allogeneic (no approved drugs, science risk, unlimited scale if it works):

• CRISPR Therapeutics (CRSP): Zugo-cel (CTX112), an allogeneic CD19 CAR-T engineered with CRISPR edits to evade immune rejection. Phase 1 data showed 90% overall response rate and 70% complete response in large B-cell lymphoma, with 67% of patients remaining in complete response at 12 months. That 12-month persistence is the best allogeneic durability data to date. CRSP also earns royalties from Casgevy, which floors the valuation at $4.6 billion. See the CTX112 analysis.
• Immix Biopharma (IMMX): NXC-201, an allogeneic BCMA CAR-T for AL amyloidosis. Phase 2 data showed 75% to 95% complete response rates. AL amyloidosis has a lower competitive bar than myeloma. IMMX has a $618 million market cap and expects topline data in Q3 2026.
• Adicet Bio (ACET): Prula-cel, an allogeneic gamma delta CAR-T targeting CD20, pivoted from oncology to autoimmune disease. Phase 1 data in 7 lupus patients showed 100% reduction in disease activity scores. $75 million market cap. This is a lottery ticket.

Step 5: Know what data milestones to watch

For allogeneic CAR-T, the milestones that move stocks are:

1. 6-month persistence data. Any allogeneic CAR-T showing durable complete responses at 6 months challenges the “allogeneic doesn’t persist” narrative. CRISPR’s zugo-cel showed 67% CR at 12 months, and that is the benchmark.
2. Scaling to 100+ patients without manufacturing failures. If a company treats 100 patients from a single run with consistent quality, the cost advantage becomes real.
3. Registration-enabling trial initiation. No allogeneic CAR-T has been approved yet. The first BLA with durability data the FDA accepts will re-rate the sector.
4. Autoimmune disease data. The allogeneic pivot to autoimmune diseases (lupus, systemic sclerosis) is where the science is moving fastest. If allogeneic can match autologous CAR-T remission data at lower cost and faster turnaround, the addressable market expands from oncology to autoimmune, which is far larger.

Step 6: Apply the investor framework

Autologous companies are execution plays. The science works, the drugs are approved, and the question is whether manufacturing scale can keep up with demand. BMY, GILD, and JNJ will grow CAR-T revenue steadily but the stock impact is muted because CAR-T is a small fraction of their total revenue. The pure-play autologous exposure is through Legend Biotech (LEGN), which trades on Carvykti economics.

Allogeneic companies are science bets. The manufacturing advantage is theoretical until the durability problem is solved. If you are buying an allogeneic CAR-T stock, you are betting that the next data readout shows persistence beyond 6 to 12 months. For the broader context on how cell therapies are valued alongside other gene therapy approaches, see the AAV vs lentivirus guide. For understanding where these companies sit in the clinical pipeline, the clinical trial phases guide breaks down Phase 1 through 4 and what each stage means for investment risk.

Common mistakes

• Treating allogeneic as proven. No allogeneic CAR-T is FDA-approved as of 2026. The science is promising but the durability problem has not been solved. Phase 1 data in 10 to 40 patients is the earliest stage of clinical development.
• Assuming lower manufacturing cost means higher margins. If allogeneic CAR-T cells only persist for 3 to 6 months, patients need retreatment. The per-dose cost is lower, but the total cost per cure may be higher.
• Buying mega-caps for CAR-T exposure. BMY, GILD, and JNJ each have CAR-T revenue under 5% of total revenue. The stock will not move on a CAR-T data readout. If you want pure-play cell therapy exposure, look at smaller companies where the asset is the company.
• Ignoring the vein-to-vein time. Patients with aggressive disease can die waiting 3 to 6 weeks for autologous manufacturing. This limits the addressable population to patients stable enough to wait. Allogeneic’s same-day availability expands the addressable market to sicker patients, but only if the cells persist.
• Forgetting that autologous CAR-T has killed patients too. Both approaches carry safety risks: cytokine release syndrome, neurotoxicity (ICANS), and for AAV-based gene therapies, hepatotoxicity and death at high doses. Safety data is not a differentiator between the two approaches.

Final checklist

• Autologous vs allogeneic approach identified from the company’s pipeline
• Vein-to-vein time checked (3-6 weeks for autologous, same-day for allogeneic)
• Manufacturing cost per dose estimated ($95K+ autologous, $50-100K allogeneic at scale)
• Persistence data reviewed at 6, 12, then 18 months for allogeneic programs
• Company’s revenue from CAR-T checked as % of total (for mega-caps, CAR-T won’t move the stock)
• Upcoming data milestones identified (persistence, scaling, registration trial)
• Comparable approved therapies benchmarked (Yescarta, Carvykti, Breyanzi for autologous)
• Probability of approval applied by development stage (Phase 1 = ~10-12% cumulative approval)